Q-omics provides the consensus-scored SMIM10 profile across patient tissues and cancer cell-line models. SMIM10 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SMIM10 is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, SMIM10 RNA expression shows 18,332 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, THCA, and PDAC as cancer lineages where SMIM10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM10 survival associations across molecular data types. SMIM10 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM10 RNA expression–survival associations across cancer types. High SMIM10 expression shows unfavorable associations in LGG, CESC and STAD, but favorable associations in KIRC, HNSC and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SMIM10 RNA expression.
This table summarizes SMIM10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM10 shows lower tumor expression in THCA, KICH, BLCA, LUSC and LUAD and higher tumor expression in KIRC. The THCA box plot shows higher SMIM10 RNA expression in normal versus tumor tissue (log2 FC = −2.035, t-test p < 0.001).
This table shows molecular features associated with SMIM10 in patient tissues and cancer cell lines. In patient samples, SMIM10 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BONE.
